Article
Oncology
Brian M. Slomovitz, Virginia L. Filiaci, Joan L. Walker, Michael C. Taub, Karen A. Finkelstein, John W. Moroney, Aimee C. Fleury, Carolyn Y. Muller, Laura L. Holman, Larry J. Copeland, David S. Miller, Robert L. Coleman
Summary: This study evaluated the efficacy and tolerability of everolimus/letrozole and medroxyprogesterone acetate/tamoxifen in the treatment of metastatic endometrial carcinoma. The results showed that both treatment regimens demonstrated clinically meaningful efficacy in patients, especially in chemotherapy-naive patients.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Genetics & Heredity
Joseph Letourneau, Flor Juarez-Hernandez, Kaitlyn Wald, Salustiano Ribeiro, Ange Wang, Charles E. McCulloch, Evelyn Mok-Lin, Milana Dolezal, A. Jo Chien, Marcelle I. Cedars, Mitchell Rosen
Summary: The study found that concomitant use of tamoxifen-gonadotropin and letrozole-gonadotropin produced a similar number of mature oocytes compared to using gonadotropin alone. Age, antral follicle count, and body mass index were also similar between the randomized groups.
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS
(2021)
Article
Oncology
Alexej Ballhausen, Jennifer J. Wheler, Daniel D. Karp, Sarina A. Piha-Paul, Siqing Fu, Shubham Pant, Apostolia M. Tsimberidou, David S. Hong, Vivek Subbiah, Veronica R. Holley, Helen J. Huang, Abenaa M. Brewster, Kimberly B. Koenig, Nuhad K. Ibrahim, Funda Meric-Bernstam, Filip Janku
Summary: The combination therapy of everolimus, letrozole, and trastuzumab showed favorable safety profile and encouraging signs of anticancer activity in patients with heavily pretreated hormone receptor- and HER2-positive advanced cancers. Some patients, particularly those with HER2 amplification, had partial responses to the treatment.
CLINICAL CANCER RESEARCH
(2021)
Article
Genetics & Heredity
Yael Shulman, Benny Almog, Yael Kalma, Yuval Fouks, Foad Azem, Yoni Cohen
Summary: A retrospective study of 118 breast cancer patients undergoing fertility preservation treatment found that letrozole or tamoxifen did not significantly affect the number of retrieved oocytes, fertilization rate, or duration of stimulation, but did impact top-quality embryo rate. Further studies are needed to confirm these findings and explore the potential negative effects of letrozole or tamoxifen on fertility preservation outcomes.
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS
(2021)
Article
Pharmacology & Pharmacy
Xing Jiang, Shengfang Jiang, Honglu Diao, Kai Deng, Changjun Zhang
Summary: Comparing the characteristics and efficacy of progestin-primed ovarian stimulation (PPOS) protocol with or without letrozole for IVF/ICSI-ET assisted pregnancy treatment revealed that the combined treatment group had higher AMH levels, longer Gn duration, less Gn and MPA dose, higher LH and progesterone levels, more retrieved oocytes and mature eggs, as well as higher fertilization and blastocyst formation rates. However, there were no significant differences in endometrial preparation and pregnancy outcomes between the groups. Logistic regression analysis identified embryo transfer stage and number as risk factors for clinical pregnancy rate.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
(2022)
Article
Cardiac & Cardiovascular Systems
Christos Papageorgiou, Flora Zagouri, Konstantinos Tampakis, Rebecca Georgakopoulou, Efstathios Manios, Pavlos Kafouris, Georgios Benetos, Iosif Koutagiar, Constantinos Anagnostopoulos, Meletios A. Dimopoulos, Konstantinos Toutouzas
Summary: This study investigated the cardiovascular burden and vascular inflammation in metastatic breast cancer patients receiving CDK 4/6 inhibitors or everolimus, showing that CDK 4/6 treatment led to increased blood pressure, vascular inflammation, and left ventricle damage compared to everolimus treatment.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Oncology
Ursula A. Matulonis, Helen Q. Huang, Virginia L. Filiaci, Marcus Randall, Paul A. DiSilvestro, Katherine M. Moxley, Jeffrey M. Fowler, Matthew A. Powell, Nick M. Spirtos, Krishnansu S. Tewari, William E. Richards, John M. Nakayama, David G. Mutch, David S. Miller, Daniela Matei, Lari B. Wenzel
Summary: Chemotherapy plus radiation did not show superiority over chemotherapy alone in treating stage III or IVA endometrial carcinoma. Although the combined treatment led to a decline in quality of life and gastrointestinal toxicity, these differences were not clinically meaningful.
GYNECOLOGIC ONCOLOGY
(2022)
Meeting Abstract
Oncology
Alexandra Spirtos, Salvatore Lococo, Matthew Carlson, Jayanthi Lea, David Miller, Jessica Lee
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Brian M. Slomovitz, Virginia L. Filiaci, Joan L. Walker, Michael C. Taub, Karen A. Finkelstein, John W. Moroney, Aimee C. Fleury, Carolyn Y. Muller, Laura L. Holman, Larry J. Copeland, David S. Miller, Robert L. Coleman
Summary: This study evaluated the efficacy and tolerability of everolimus/letrozole and medroxyprogesterone acetate/tamoxifen in the treatment of metastatic endometrial carcinoma. The results showed that both treatment regimens demonstrated clinically meaningful efficacy in patients, especially in chemotherapy-naive patients.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Matthew A. Powell, Virginia L. Filiaci, Martee L. Hensley, Helen Q. Huang, Kathleen N. Moore, Krishnansu S. Tewari, Larry J. Copeland, Angeles A. Secord, David G. Mutch, Alessandro Santin, David P. Warshal, Nick M. Spirtos, Paul A. DiSilvestro, Olga B. Ioffe, David S. Miller
Summary: This phase III randomized trial compared the efficacy of paclitaxel and carboplatin (PC) with paclitaxel and ifosfamide (PI) in the treatment of uterine carcinosarcoma. The results showed that PC was not inferior to PI and should be considered as the standard treatment for uterine carcinosarcoma.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
V Makker, N. Colombo, A. Casado Herraez, A. D. Santin, E. Colomba, D. S. Miller, K. Fujiwara, S. Pignata, S. Baron-Hay, I Ray-Coquard, R. Shapira-Frommer, K. Ushijima, J. Sakata, K. Yonemori, Y. M. Kim, E. M. Guerra, U. A. Sanli, M. M. McCormack, A. D. Smith, S. Keefe, S. Bird, L. Dutta, R. J. Orlowski, D. Lorusso
Summary: Lenvatinib plus pembrolizumab significantly prolongs progression-free survival and overall survival compared to chemotherapy in advanced endometrial cancer patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Editorial Material
Obstetrics & Gynecology
Linda Van Le
Summary: This study aimed to compare the efficacy and safety of lenvatinib plus pembrolizumab with chemotherapy in patients with platinum-refractory advanced endometrial cancer. The results showed that lenvatinib plus pembrolizumab significantly improved progression-free survival and overall survival, with better effects observed in pMMR patients. Similar results were observed in the overall population.
OBSTETRICAL & GYNECOLOGICAL SURVEY
(2022)
Article
Obstetrics & Gynecology
Jessica E. Parker, Caitlin Mauer, Wenxin Zheng, David S. Miller, Jayanthi S. Lea
Summary: The frequency of Lynch syndrome differs between type I and type II endometrial cancers, with age-based screening being effective in diagnosing Lynch syndrome in type I cases but not in type II cases. These findings highlight the importance of a universal screening approach for type II endometrial cancer patients, even in low-resource populations.
CURRENT WOMENS HEALTH REVIEWS
(2022)
Article
Oncology
Yovanni Casablanca, Guisong Wang, Heather A. Lankes, Chunqiao Tian, Nicholas W. Bateman, Caela R. Miller, Nicole P. Chappell, Laura J. Havrilesky, Amy Hooks Wallace, Nilsa C. Ramirez, David S. Miller, Julie Oliver, Dave Mitchell, Tracy Litzi, Brian E. Blanton, William J. Lowery, John Risinger, Chad A. Hamilton, Neil T. Phippen, Thomas P. Conrads, David Mutch, Katherine Moxley, Roger B. Lee, Floor Backes, Michael J. Birrer, Kathleen M. Darcy, George Larry Maxwell
Summary: This study developed a risk assessment model for metastasis and prognosis in endometrioid endometrial cancer (EEC) using molecular and clinical features. The model, called MS7, showed higher accuracy in predicting the chance of nodal and distant metastasis compared to clinical factors. MS7 score also accurately indicated bad outcomes such as cancer progression and death. This research has important implications for guiding patient care and optimizing treatment strategies for EEC.
Review
Oncology
Ignace Vergote, Teresa Macarulla, Fred R. Hirsch, Carsten Hagemann, David Scott Miller
Summary: Tumor Treating Fields (TTFields) are electric fields that inhibit cancer cell survival and tumor growth without harming healthy cells. TTFields therapy delivers the treatment to the tumor site noninvasively using skin arrays. Taxanes are commonly used chemotherapies that have side effects, and alternative treatments that enhance their efficacy without increasing side effects are needed.
Article
Oncology
Domenica Lorusso, Nicoletta Colombo, Antonio Casado Herraez, Alessandro D. Santin, Emeline Colomba, David Scott Miller, Keiichi Fujiwara, Sandro Pignata, Sally E. Baron-Hay, Isabelle Laure Ray-Coquard, Ronnie Shapira-Frommer, Yong Man Kim, Mary Mccormack, Rachid Massaad, Allison Martin Nguyen, Qi Zhao, Jodi Mckenzie, Vimalanand S. Prabhu, Vicky Makker
Summary: In the phase 3 study 309/KEYNOTE-775, Lenvatinib and pembrolizumab (LEN+PEMBRO) showed significant improvements in efficacy compared to treatment of physician's choice (TPC) for patients with advanced endometrial cancer (aEC). Health-related quality of life (HRQoL) was reported.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Christopher A. Walker, Alexandra N. Spirtos, David S. Miller
Summary: Advanced and recurrent endometrial carcinoma is difficult to treat, especially for patients who are microsatellite stable (MSS) or mismatch repair proficient (pMMR). Recent trials have shown that the combination of pembrolizumab and lenvatinib improves ORR, PFS, and OS compared to current therapies.
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Article
Oncology
Steven B. Holloway, Alyssa J. Mercadel, David S. Miller, Jayanthi S. Lea
Summary: This study investigated the impact of para-aortic lymphadenectomy on the outcomes of patients with cervical cancer undergoing surgery. The results showed that omitting para-aortic lymphadenectomy, in the absence of suspicious lymph nodes, did not decrease survival.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Vicky Makker, Nicoletta Colombo, Antonio Casado Herraez, Bradley J. Monk, Helen Mackay, Alessandro D. Santin, David S. Miller, Richard G. Moore, Sally Baron-Hay, Isabelle Ray-Coquard, Kimio Ushijima, Kan Yonemori, Yong Man Kim, Eva M. Guerra Alia, Ulus A. Sanli, Steven Bird, Robert Orlowski, Jodi McKenzie, Chinyere Okpara, Gianmaria Barresi, Domenica Lorusso
Summary: This article reports the final prespecified analysis of the Study 309/KEYNOTE-775, which is an open-label, randomized, phase III trial. The results show that lenvatinib plus pembrolizumab improves overall survival, progression-free survival, and objective response rate compared to chemotherapy in patients with advanced endometrial cancer. The combination therapy also demonstrates improved efficacy and manageable safety in various subgroups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Vicky Makker, Nicoletta Colombo, Antonio Casado Herraez, Bradley Monk, Helen Mackay, Alessandro Santin, David Miller, Richard Moore, Isabelle Ray-Coquard, Ronnie Shapira-Frommer, Kimio Ushijima, Kan Yonemori, Yong Man Kim, Eva Guerra Alia, Ulus Sanli, Ran Xie, Melissa Zale, Jodi Mckenzie, Gianmaria Barresi, Domenica Lorusso
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Meeting Abstract
Oncology
Vicky Makker, Nicoletta Colombo, Alessandro Santin, David Scott Miller, Keiichi Fujiwara, Sandro Pignata, Isabelle Laure Ray-Coquard, Yong Man Kim, Eva M. Guerra, Jie Huang, Gianmaria Barresi, Jodi McKenzie, Domenica Lorusso
JOURNAL OF CLINICAL ONCOLOGY
(2022)
